Jun 1, 2025, 12:49

Notice of Special Interest: RNA Modifications in Cancer Biology

This NOSI from the National Cancer Institute (NCI) aims to stimulate small, investigator-initiated projects that elucidate how chemical modifications of RNA contribute to cancer onset, progression, and phenotype. It encourages development or improvement of methods to map, quantify, and functionally characterize RNA “writers,” “erasers,” and “readers,” and to define how dysregulation of those processes drives tumorigenesis. Funded projects should generate foundational data suitable for subsequent R01‐type applications.

Eligibility Criteria

Applications must be submitted in response to one of the following parent FOAs, citing NOT-CA-23-060 in box 4B of the SF424(R&R):
- R21: PA-20-195 (NIH Exploratory/Development Research Grant Program; clinical trial not allowed)
- R03: PAR-23-058 (NCI Omnibus Small Grants; clinical trial optional)
- R61: RFA-CA-23-002 (Innovative Molecular and Cellular Analysis Technologies; clinical trial not allowed)
- R33: RFA-CA-23-003 (Advanced Development and Validation of Emerging Technologies; clinical trial not allowed)
- R21: RFA-CA-23-014 (Informatics Methods and Algorithms for Cancer Research; clinical trial optional)
- U01: RFA-CA-23-015 (Early-Stage Development of Informatics Technologies; clinical trial optional)
Any institution or investigator otherwise eligible under the parent FOA may apply (e.g., higher education institutions, nonprofits, for-profit organizations, government entities, foreign organizations).
Applications that do not include “NOT-CA-23-060” in the Agency Routing Identifier (box 4B) of the SF424(R&R) will be ineligible for this NOSI.

Funding Details

Projects will be funded through the mechanism-specific budget and project‐period limits defined in each parent FOA. Applicants must follow all SF424(R&R) Application Guide instructions and any FOA‐specific guidelines.
Because this is a NOSI, NCI is not formally listed as a participating organization on every parent announcement; however, applications responding to NOT-CA-23-060 will be accepted under each FOA through the expiration date.
Peer review and award decisions will follow the review criteria and funding parameters of the parent FOA.

Deadline

First Available Due Dates (and recurring dates through expiration, as specified in each FOA):

• R21 (PA-20-195): June 16, 2023

• R03 (PAR-23-058): June 20, 2023

• R61 (RFA-CA-23-002) & R33 (RFA-CA-23-003): September 1, 2023

• R21 (RFA-CA-23-014) & U01 (RFA-CA-23-015): June 13, 2023
Expiration Date (final receipt date): January 8, 2026
Subsequent due dates and any revisions to parent FOAs should be consulted on grants.nih.gov.

Where to Go for Further Information

Review the full NOSI text at grants.nih.gov.
Access each parent FOA on Grants.gov (search by its FOA number).
Address scientific or technical questions to:

• Stefan Maas, Ph.D.
- Tel: 240-276-6230 Email: [email protected]
Address budget or administrative questions to:

• Amy R. Bartosch
- Tel: 240-276-6375 Email: [email protected]

biomedical innovation cancer Cancer research cooperative agreement grant funding IMAT program innovative technology molecular analysis technologies National Cancer Institute NCI IMAT NIH grant OncoDaily Oncology research collaboration U01

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology

How Artificial Intelligence Is Transforming Cancer Care in 2025: Diagnosis, Treatment, Clinical Trials, and Screening

Inside ASCO25 Exhibition - Who did it the best?

Douglas Flora: Fighting Cancer with Heart